CloudLIMS - Laboratory Information Management System (LIMS) Software Podcasts

Are cannabis testing labs truly the goldmine many believe them to be? While the potential for profit is undeniable, the cost structure can be complex. Beneath the surface, significant hidden costs can catch newcomers as well as established labs off guard. 

In this episode, we sit down with Ini Afia, a seasoned expert in the cannabis industry, to uncover the financial intricacies of running a cannabis testing lab. We discuss the high setup costs, including multimillion-dollar equipment, specialized lab spaces, staffing requirements, inventory, consumables, and utility costs.

When selecting testing instruments, Ini emphasizes the importance of considering the total cost of ownership—including purchase price, maintenance costs, and the cost of spare parts. He highlights the value of preventative maintenance in extending the lifespan of expensive instruments and minimizing unexpected breakdowns. Additionally, he sheds light on often-overlooked expenses, such as reagents and consumables, offering strategies to reduce costs.

Staff training can also be a significant expense. Ini suggests cost-effective methods such as e-learning, on-the-job training, and cross-training staff to minimize external training costs. However, he cautions that employees must first be proficient in their core skills before cross-training.

For lab owners, regulatory compliance and waste management pose additional financial challenges. Ini explains how labs can effectively manage cannabis waste to avoid regulatory penalties and optimize the use of chemicals, reagents, and consumables so that costs don’t spiral out of control. 

He also underscores the role of a cloud-based cannabis LIMS in managing large data volumes, preventing data loss, and meeting compliance. However, he warns that hidden LIMS costs—such as fees for instrument integration, product training, and CoA templates—can add up. He advises lab owners to choose a LIMS provider that offers these services at no additional cost to reduce the total ownership cost.

To wrap up, Ini shares insights into contingency planning to navigate unexpected disruptions and highlights emerging industry trends, such as standardized testing methods and strategic lab partnerships, that can drive further cost savings.

If you’re considering entering the cannabis testing business or looking to optimize costs in an existing lab, this episode is a must-watch.

1. Why are cannabis testing labs usually expensive to start, and what are the key areas where costs add up quickly?
2. What factors should lab owners consider when selecting testing instruments to balance cost and quality?
3. In terms of consumables, what are the most overlooked expenses, and how can lab managers reduce these costs?
4. Staff training is essential but costly. How can labs reduce training expenses while ensuring staff remain proficient and compliant with regulations?
5. One of the most expensive aspects that prospective and existing lab owners don’t realize until it’s too late is the cost of maintenance plans for their multimillion-dollar instruments. What role does proper equipment maintenance play in controlling long-term costs for cannabis testing labs, and how can labs choose the right maintenance plans?
6. Getting certifications, accreditations, and regulatory approvals can take a lot of time and money. What strategies can new lab owners use to reduce these expenses and stay on the right side of the regulations?
7. How can waste reduction, proper disposal, and recycling initiatives help lab owners reduce costs?
8. How can informatics tools, such as a LIMS, help lab owners improve efficiency, optimize resource utilization, and ensure quality management while minimizing costs?
9. Effective contingency planning is crucial for uninterrupted lab operations. How can labs budget and plan to minimize financial impact during unforeseen disruptions?
10. As more states legalize cannabis, what additional cost-saving trends do you see emerging in the cannabis industry?

Lab managers, owners, quality managers, and technicians in both emerging and established cannabis testing labs.

When you select a product at a grocery store, whether it is a can of soup, a bottle of juice, or a box of cereal, you likely check the label for ingredients, nutritional facts, and any certification marks. You trust the information provided on these labels is accurate and reliable. But what happens when the information on those labels is misleading or worse, completely wrong? This is a concern that is not just limited to food products; it extends to the cannabis industry as well, where consumers rely on the certificate of analysis (COA) to ensure the safety, potency, and compliance of the products they consume. Striking but not uncommon instances of COA manipulation have surfaced, where inaccurate or fabricated results are reported to customers, either unintentionally or as a result of fraudulent behavior. 

In this podcast, we explore the critical role of COAs in ensuring product quality and safety, and discuss the potential for fraud and manipulation within the industry with Dr. Susan Audino, Chemistry Laboratory Consultant at S. A. Audino & Associates, LLC, and a member of the Scientific Advisory Board (SAB) at CloudLIMS. 

Dr. Audino begins by defining what a COA is and explores the alarming issue of COA fraud, its impact on public health, and how manipulations of test reports can have long-lasting repercussions on industry reputation and consumer trust. Dr. Audino delineates the ways some laboratories are under pressure to meet customer expectations, which sometimes leads to bending or breaking the rules. The discussion also covers the limitations of laboratory accreditation and throws light on how labs, regulators, and manufacturers contribute to the current challenges in the cannabis testing landscape. We also discuss the role of informatics tools such as a modern cannabis LIMS in improving transparency in the cannabis industry and ensuring consumer trust. 

Tune in to the conversation for these and more such insights and perspectives on the state of cannabis testing and the need for aligning the market’s vocabulary, values, and assumptions with ethical practices.

1. What is a COA?
2. What are some common methods of COA fraud, and what far-reaching consequences can they have for public health, regulatory compliance, and the industry’s reputation?
3. Despite well-intentioned efforts, the industry has encountered significant challenges, including litigation, THC inflation, and disparaging mudslinging. What are the factors that contribute to these challenges?
4. What are some real-world examples of how laboratories exploit the principles of analytical chemistry to meet customer needs without regard for scientific integrity and the accuracy of test results?
5. What are the limitations of laboratory accreditation and the potential risks associated with assuming that all accredited labs are equally competent?
6. How do informatics tools help authenticate results and enable consumers to verify the composition stated on product labels?
7. How do current regulatory frameworks affect the integrity of testing and reporting in the cannabis industry? Do some regulations need reform?
8. Advice for stakeholders, for example, how should laboratories operate and provide test results consumers can trust? And on the other hand, how can consumers ensure they are getting what they are paying for and consuming a safe product?

Lab managers, directors, quality managers, and technicians of cannabis testing labs.

In this podcast, we unravel the significance of proficiency testing (PT) in the cannabis industry with Morgan Keefer, Accreditation Officer II at A2LA. 

We dive headfirst into the subject by demystifying PT, exploring its significance in ensuring the accuracy and reliability of cannabis test results. Morgan elaborates on the cannabinoids, microbial, and chemical attributes typically analyzed during PT. 

Morgan’s expertise guides the discussion on the PT and interlaboratory comparison (ILC) requirements essential for ISO/IEC 17025 accreditation along with best practices for effective PT preparation. We also discuss the frequency of PT participation mandated by state regulatory bodies, highlighting the diverse timelines across different states. 

Keefer explains how PT results are statistically evaluated and interpreted by PT providers to pass or fail a lab. She also discusses the impact of matrix interferences and sample heterogeneity on result accuracy. Furthermore, she provides tips for laboratories failing PT to determine the root cause and plan of action to remedy the failure. The discussion extends to practical examples of how PT has directly enhanced the operational efficiency and credibility of cannabis testing labs. Morgan also shares her foresight on advancements in PT for cannabis labs as testing requirements evolve. The podcast concludes with Morgan emphasizing the importance of informatics tools, including LIMS, in cannabis testing to support PT processes.

Tune in to the conversation for these and more such insights and gain a deeper understanding of the role PT plays in ensuring quality assurance and compliance in the dynamic and rapidly evolving cannabis industry.

• What is PT and why is it crucial for cannabis testing labs? 
• What are some of the cannabinoids, microbial, and chemical attributes that cannabis labs typically test for during proficiency testing, and why are these important? 
• What are PT and ILC requirements for ISO/IEC 17025 accreditation? What are the best practices for cannabis labs to effectively prepare for proficiency testing? 
• How often labs are required to participate in proficiency testing to meet state regulatory requirements? Does the timeline vary from one state to another? 
• How are PT results evaluated using statistical methods and interpreted by PT providers to pass or fail a lab in proficiency testing? 
• How do matrix interferences and sample heterogeneity impact the accuracy and reliability of test results? And, what measures should labs take to minimize their effects? 
• In the event that a laboratory fails PT, what is the recommended procedure for review along with a plan of action to correct the problems found?
• What are some practical examples of how proficiency testing has directly improved the operations or credibility of cannabis testing labs?
• What are the limitations of proficiency testing for cannabis labs and how can PT be improved for cannabis labs?
• Is proficiency testing more challenging for the cannabis industry compared to other industries, such as the food industry, due to the federal illegality of cannabis? If so, in what aspects?
• As cannabis testing requirements continue to evolve, what advancements or developments do you foresee in the field of proficiency testing for cannabis labs?
• How do informatics tools support proficiency testing in cannabis labs?

Lab managers, directors, quality managers, and technicians of cannabis testing labs.

In an era of heightened emphasis on climate action, the decarbonization imperative extends to biobanks, recognized as essential but energy-intensive research infrastructures. 

With rich experience as the Head of Laboratory Support, Biobanking, and Services at IARC/WHO, Zisis Kozlakidis brings a seasoned perspective to our podcast, articulately delving into the crucial facets of biobanking, from environmental challenges to innovative solutions and the future landscape of sustainable practices in healthcare and research.

In this podcast, Zisis addresses the pressing environmental challenges associated with traditional biobanking practices and their contribution to carbon emissions. He sheds light on the unique challenges faced by biobanks in lower and middle-income countries (LMICs) and unveils potential strategies for reducing their carbon footprint. Zisis provides insights into the innovative technologies adopted by high-income countries (HICs) to reduce energy consumption in biobanking and shares real-world examples of biobanking facilities successfully implementing decarbonization strategies. He explores the potential of informatics tools in reducing carbon footprint and provides invaluable advice for biobanks initiating their decarbonization journey. Zisis concludes by painting a vision of a future biobanking landscape, emphasizing its transformative impact on healthcare and global research.

Tune in to the podcast for these insightful discussions with Zisis Kozlakidis, shedding light on the path towards sustainable and environmentally conscious biobanking practices.

• What are the key environmental challenges associated with traditional biobanking practices, and how do they contribute to carbon emissions?
• Considering the global impact of biobanking, how important is it for the biobanking community to engage in a dialogue about its environmental impact and incorporate sustainability measures into its governance practices?
• What are the unique challenges biobanks in lower and middle-income countries (LMICs) face when trying to reduce their carbon footprint? Also, what are some potential solutions or strategies for biobanks in LMICs to reduce their carbon emissions?
• What role should governments, policymakers, and the broader scientific community play in prioritizing decarbonization efforts in biobanking, especially in LMICs?
• What are some examples of innovative technologies and equipment that HICs are adopting to reduce energy consumption in biobanking?
• Should biobanks gather data about the cost and consumption of liquid nitrogen and energy over the lifetime of freezers for successful decarbonization efforts, and what challenges exist in obtaining such data?
• What are some real-world examples of biobanking facilities successfully implementing decarbonization strategies?
• What are some cutting-edge technologies on the horizon that could transform biobanking and its approach to sustainability?
• Are informatics tools recommended for biobanks to reduce their carbon footprint?
• What are the first steps biobanks embarking on a journey towards decarbonization should consider?
• What does the future biobanking landscape look like in terms of decarbonization goals, and how might this impact healthcare and research on a global scale?

Biobank managers, quality managers, and technicians.

Disclaimer

Where individuals are identified as personnel of the International Agency for Research on Cancer/WHO, these individuals alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer/WHO.